ERBB2 and neoplasm: By combining the enzyme responsiveness of ET‐CORM with the tumor‐targeting specificity of trastuzumab, our platform achieves dual‐layer cancer selectivity, leveraging both HER2 overexpression and intracellular CatB activity for precise CO release.